产品

您的位置:首页 > 食品资讯 > 外讯导读 > 欧盟评估卡琪花蒂玛水醇提取物作为新型食品的安全性

欧盟评估卡琪花蒂玛水醇提取物作为新型食品的安全性

来源:好招商食品网 外讯导读   |  2024-04-25
   好招商食品网讯  2022年11月10日,据欧盟食品安全局(EFSA)消息,欧盟营养、新型食品和食物过敏原(NDA)研究小组就卡琪花蒂玛水醇提取物(an aqueous ethanolic extract of Labisia pumila)作为新型食品的安全性发表科学意见。
 
  经过评估,专家小组得出结论,卡琪花蒂玛水醇提取物作为新型食品在350毫克/天以下对目标人群是安全的。部分原文报道如下:
 
  Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on aqueous extract of Labisia pumila as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is a standardised hydroalcoholic extract from a dried whole plant (including roots) of L. pumila, mixed with maltodextrin (as a drying aid), and proposed by the applicant to be used as a food supplement in amounts up to 750 mg/day. The target population is the general adult population, except pregnant and lactating women. The major constituents of this NF are carbohydrates (up to 85.5%), with a smaller amount of proteins (up to 6.5%), gallic acid (up to 3.7%) and fats (up to 1.6%). The Panel considers that taking into account the composition of the NF and the proposed conditions of use, consumption of the NF is not nutritionally disadvantageous. The provided genotoxicity studies do not raise concerns about the genotoxicity of the NF. based on the available toxicological data, the Panel considers an intake of up to 5 mg/kg body weight per day as safe. For the target population, this level corresponds to 350 mg/day, which is lower than the use level proposed by the applicant. The Panel concludes that the NF is safe for the target population up to 350 mg/day.
 

TAGS:过敏原 食品 安全局 提取物 食品安全
免责声明:本站部分文章转载自网络,图文仅供行业学习交流使用,不做任何商业用途。文章仅代表原作者个人观点,其原创性及文章内容中图文的真实性、完整性等未经本站核实,仅供读者参考。
上一篇: 欧盟评估转基因大豆40-3-2的授权更新申请
下一篇: 欧盟发布关于多效唑的最大残留限量审查后确认数据的评估